Clin2
NCT06769139Possibly a fitNot yet recruiting

How red blood cell exchange affects inflammation in sickle cell disease

Sickle Cell Disease

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This study looks at whether red blood cell exchange (a treatment that replaces some of your blood with donor blood) can help reduce inflammation and blood clotting problems in people with sickle cell disease. If you are already on this treatment, it may help doctors understand how it affects your body.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
20 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have sickle cell disease with the SS or S/beta thalassemia type.
  • You have been on red blood cell exchange (a blood replacement treatment) for more than 3 months.
  • You have health insurance (social security) and can understand the study.
  • You are not pregnant or breastfeeding, and do not have a very low platelet count (below 50).
  • You have not taken NSAID pain relievers or blood thinners in the last 7 days.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03279094Recruiting· Phase 1
Testing a half-matched bone marrow transplant for sickle cell

This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.

Duarte, California
NCT06944067Recruiting
Genetic risk of immune response after blood transfusions in sickle cell disease

This study looks at whether certain genes make people with sickle cell disease more likely to develop an immune reaction to blood transfusions. It aims to help doctors predict transfusion risks and improve care.

Bethesda, Maryland
NCT07000318Not yet recruiting· Early Phase 1
CS-206 for sickle cell disease in teens

This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.

Shanghai, Shanghai Municipality
NCT06565026Recruiting· Early Phase 1
CS-206 treatment for sickle cell disease patients

This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.

Nanning, Guangxi
NCT07341022Not yet recruiting· Phase 1/Phase 2
Stem cell collection study for sickle cell disease patients

This trial tests a high-dose medicine to collect stem cells from young adults with sickle cell disease. It aims to prepare for a transplant that could potentially cure the condition.

NCT03587272Recruiting· Phase 2
Sibling bone marrow transplant to reduce treatment side effects

This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.

Washington D.C., District of Columbia

Hear when a new Sickle Cell Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.